Abintus Bio engages in the field of in vivo immune cell reprogramming.
Abintus Bio has raised $13.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in August 2022.
Abintus Bio's investors include Blood Cancer United, Inc., TCA Venture Group, SeedFolio.
Abintus Bio is headquartered in San Diego, United States.
Abintus Bio engages in the field of in vivo immune cell reprogramming.
Abintus Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Abintus Bio — Funding & Investors." VCBacked, August 15, 2022, https://www.vcbacked.co/company/abintus-bio. Accessed August 14, 2026.
VCBacked. (2022). Abintus Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/abintus-bio
{{cite web |title=Abintus Bio — Funding & Investors |url=https://www.vcbacked.co/company/abintus-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated